Preethi Sundaram Catalyst Pharmaceuticals, Inc. (CPRX) insider trading activity

CPRX Quotes by TradingView

Preethi Sundaram is Chief Strategy Officer of CATALYST PHARMACEUTICALS, INC.. Currently has a direct ownership of 41,081 shares of CPRX, which is worth approximately $860,646. The most recent transaction as insider was on Jun 11, 2025, when has been sold 1,600 shares (Common Stock, par value $0.001 per share) at a price of $26.42 per share, resulting in proceeds of $42,272. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 41.1K
8.72% 3M change
60.84% 12M change
Total Value Held $860,646

Preethi Sundaram Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 11 2025
SELL
Open market or private sale
$42,272 $26.42 p/Share
1,600 Reduced 3.75%
41,081 Common Stock, par valu...
Jun 10 2025
SELL
Open market or private sale
$61,376 $26.41 p/Share
2,324 Reduced 5.16%
42,681 Common Stock, par valu...
Feb 14 2025
SELL
Payment of exercise price or tax liability
-
5,965 Reduced 11.7%
45,005 Common Stock, par valu...
Feb 14 2025
BUY
Exercise of conversion of derivative security
-
16,667 Added 24.64%
50,970 Common Stock, par valu...
Dec 27 2024
SELL
Payment of exercise price or tax liability
-
2,345 Reduced 6.4%
34,303 Common Stock, par valu...
Dec 27 2024
BUY
Exercise of conversion of derivative security
-
6,667 Added 15.39%
36,648 Common Stock, par valu...
Dec 09 2024
SELL
Payment of exercise price or tax liability
-
2,415 Reduced 7.45%
29,981 Common Stock, par valu...
Dec 09 2024
BUY
Exercise of conversion of derivative security
-
6,855 Added 17.46%
32,396 Common Stock, par valu...
Feb 15 2024
SELL
Payment of exercise price or tax liability
-
6,025 Reduced 19.09%
25,541 Common Stock, par valu...
Feb 15 2024
BUY
Exercise of conversion of derivative security
-
16,667 Added 34.56%
31,566 Common Stock, par valu...
Dec 27 2023
SELL
Payment of exercise price or tax liability
-
2,409 Reduced 13.92%
14,899 Common Stock, par valu...
Dec 27 2023
BUY
Exercise of conversion of derivative security
-
6,666 Added 27.81%
17,308 Common Stock, par valu...
Feb 15 2023
SELL
Payment of exercise price or tax liability
-
6,024 Reduced 36.15%
10,642 Common Stock, par valu...
Feb 15 2023
BUY
Exercise of conversion of derivative security
-
16,666 Added 50.0%
16,666 Common Stock, par valu...
Nov 11 2022
SELL
Open market or private sale
$930,154 $16.38 p/Share
56,786 Reduced 100.0%
0 Common Stock, par valu...
Nov 11 2022
BUY
Exercise of conversion of derivative security
$311,755 $5.49 p/Share
56,786 Added 50.0%
56,786 Common Stock, par valu...
Sep 15 2022
SELL
Open market or private sale
$263,921 $14.49 p/Share
18,214 Reduced 100.0%
0 Common Stock, par valu...
Sep 15 2022
BUY
Exercise of conversion of derivative security
$99,995 $5.49 p/Share
18,214 Added 50.0%
18,214 Common Stock, par valu...
PS

Preethi Sundaram

Chief Strategy Officer
Coral Gables, FL

Track Institutional and Insider Activities on CPRX

Follow CATALYST PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CPRX shares.

Notify only if

Insider Trading

Get notified when an Catalyst Pharmaceuticals, Inc. insider buys or sells CPRX shares.

Notify only if

News

Receive news related to CATALYST PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CPRX